| ID | 117182 |
| Author |
Hatakeyama, S
Sakamoto Hospital
Okada, M
Tokushima University
Iwatsuki, N
Sakamoto Hospital
Sakamoto, K
Sakamoto Hospital
Ogawa, T
Sakamoto Hospital
|
| Keywords | Oral hypoglycemic agent (OHA)
Imeglimin
Twymeeg
Tetrahydrotriazine
Trials of IMeglimin for Efficacy and Safety (TIMES)
|
| Content Type |
Journal Article
|
| Description | Background: A novel oral hypoglycemic agent (OHA) would be imeglimin (Twymeeg) as tetrahydrotriazine-containing drug.
Case presentation: The patient is 93-year-old female and developed appetite loss and slower vocal response in March, 2022. Result: She was transferred to our hospital, and diagnosed as T2DM with HbA1c 8.4% and small lacunar infarction in bilateral white matter by MRI. Then, imeglimin 2000mg/day was started and HbA1c was decreased to 6.2% in April, 2020. Discussion: Imeglimin has dual function for increasing insulin secretion and decreasing insulin resistance. It seems to be effective for elderly case, and will be used widely in the future. |
| Journal Title |
International Journal of Endocrinology and Diabetes
|
| ISSN | 26943875
|
| Publisher | Pubtexto Publishers
|
| Volume | 5
|
| Issue | 2
|
| Start Page | 137
|
| Published Date | 2022-05-28
|
| Rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
